Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track NOTV with free AI briefings, catalyst countdowns, and dilution alerts.

NOTV · Inotiv, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

Chapter 11 bankruptcy. Inotiv filed for Chapter 11 bankruptcy protection on Jun 3, 2026 (8-K, Item 1.03). Read the filing
$15.2M Cash on Hand
14mo Cash Runway
Follow NOTV by email Get an email when NOTV reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about NOTV, unsubscribe in one click. Privacy

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus

Also used in these trials (approved or third-party drugs, not NOTV's own candidates): Spinosad.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

NOTV holds $15.2M in cash and short-term investments (as of Mar 31, 2026) and burns about $3.3M/quarter from operations, an estimated runway of 14 months at that rate (BioRadar estimate, not company guidance).

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NOTV files for a raise →

Get the full NOTV picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NOTV and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.